{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T13:51:34Z","timestamp":1790603494250,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","gynecologiconcology-online.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.ygyno.2024.06.026","type":"journal-article","created":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T16:28:28Z","timestamp":1720628908000},"page":"30-36","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Basket study of oral progesterone antagonist onapristone extended release in progesterone receptor-positive recurrent granulosa cell, low-grade serous ovarian cancer, or endometrioid endometrial cancer"],"prefix":"10.1016","volume":"189","author":[{"given":"Sarah","family":"Andres","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"Finch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexia","family":"Iasonos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Girshman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi","family":"Chhetri-Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hunter","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dasom","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roisin","family":"O'Cearbhaill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrisann","family":"Kyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicky","family":"Makker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis S.","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Sonoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Aghajanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Weigelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel N.","family":"Grisham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ygyno.2024.06.026_bb0005","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ygyno.2009.03.001","article-title":"Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant","volume":"114","author":"Gershenson","year":"2009","journal-title":"Gynecol. Oncol."},{"issue":"9","key":"10.1016\/j.ygyno.2024.06.026_bb0010","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1136\/ijgc-2023-004610","article-title":"Low-grade serous ovarian cancer: expert consensus report on the state of the science","volume":"33","author":"Grisham","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"24","key":"10.1016\/j.ygyno.2024.06.026_bb0015","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13246275","article-title":"Recurrent endometrial Cancer: local and systemic treatment options","volume":"13","author":"Rutten","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.ygyno.2024.06.026_bb0020","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.ygyno.2019.10.013","article-title":"Carboplatin-paclitaxel compared to carboplatin-paclitaxel-bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - a randomized phase II trial","volume":"155","author":"Lorusso","year":"2019","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2024.06.026_bb0025","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.ygyno.2024.06.026_bb0030","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ygyno.2006.07.038","article-title":"Treatment with paclitaxel plus carboplatin, alone or with irradiation, of advanced or recurrent endometrial carcinoma","volume":"104","author":"Arimoto","year":"2007","journal-title":"Gynecol. Oncol."},{"issue":"33","key":"10.1016\/j.ygyno.2024.06.026_bb0035","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1200\/JCO.20.01076","article-title":"Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a phase III trial (NRG oncology\/GOG0209)","volume":"38","author":"Miller","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.ygyno.2024.06.026_bb0040","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1016\/j.ejca.2014.09.003","article-title":"Loss of progesterone receptor links to high proliferation and increases from primary to metastatic endometrial cancer lesions","volume":"50","author":"Tangen","year":"2014","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2024.06.026_bb0045","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ygyno.2003.11.008","article-title":"Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a gynecologic oncology group study","volume":"92","author":"Fiorica","year":"2004","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2024.06.026_bb0050","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/1471-0528.17331","article-title":"The effect of progestin therapy in advanced and recurrent endometrial cancer: a systematic review and meta-analysis","volume":"130","author":"van Weelden","year":"2023","journal-title":"BJOG"},{"issue":"3","key":"10.1016\/j.ygyno.2024.06.026_bb0055","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.ygyno.2019.06.011","article-title":"PARAGON: a phase II study of anastrozole in patients with estrogen receptor-positive recurrent\/metastatic low-grade ovarian cancers and serous borderline ovarian tumors","volume":"154","author":"Tang","year":"2019","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2024.06.026_bb0060","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ygyno.2021.07.024","article-title":"A phase 2 study of anastrozole in patients with oestrogen receptor and\/progesterone receptor positive recurrent\/metastatic granulosa cell tumours\/sex-cord stromal tumours of the ovary: the PARAGON\/ANZGOG 0903 trial","volume":"163","author":"Banerjee","year":"2021","journal-title":"Gynecol. Oncol."},{"issue":"15","key":"10.1016\/j.ygyno.2024.06.026_bb0065","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14153681","article-title":"Traditional systemic treatment options in advanced low-grade serous ovarian cancer after successful cytoreduction: a systematic review and meta-analysis","volume":"14","author":"Montero-Macias","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.ygyno.2024.06.026_bb0070","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ygyno.2014.03.573","article-title":"Hormone therapy in ovarian granulosa cell tumors: a systematic review","volume":"134","author":"van Meurs","year":"2014","journal-title":"Gynecol. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2024.06.026_bb0075","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12061398","article-title":"Molecular pathways and targeted therapies for malignant ovarian germ cell tumors and sex cord-stromal tumors: a contemporary review","volume":"12","author":"Maoz","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.ygyno.2024.06.026_bb0080","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/pgp.0b013e31805c0d99","article-title":"Estrogen receptor alpha and progesterone receptor expression in ovarian adult granulosa cell tumors and Sertoli-Leydig cell tumors","volume":"26","author":"Farinola","year":"2007","journal-title":"Int. J. Gynecol. Pathol."},{"issue":"10","key":"10.1016\/j.ygyno.2024.06.026_bb0085","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1200\/JCO.2016.71.0632","article-title":"Hormonal maintenance therapy for women with low-grade serous Cancer of the ovary or peritoneum","volume":"35","author":"Gershenson","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2024.06.026_bb0090","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ygyno.2017.02.029","article-title":"Hormone receptor expression profile of low-grade serous ovarian cancers","volume":"145","author":"Buttarelli","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"9","key":"10.1016\/j.ygyno.2024.06.026_bb0095","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1470-2045(13)70253-5","article-title":"Hormone-receptor expression and ovarian cancer survival: an ovarian tumor tissue analysis consortium study","volume":"14","author":"Sieh","year":"2013","journal-title":"Lancet Oncol."},{"issue":"48","key":"10.1016\/j.ygyno.2024.06.026_bb0100","doi-asserted-by":"crossref","first-page":"84019","DOI":"10.18632\/oncotarget.20251","article-title":"Hormone receptors expression in ovarian cancer taking into account menopausal status: a retrospective study in Chinese population","volume":"8","author":"Shen","year":"2017","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.ygyno.2024.06.026_bb0105","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.ygyno.2015.06.037","article-title":"Development of a technique to detect the activated form of the progesterone receptor and correlation with clinical and histopathological characteristics of endometrioid adenocarcinoma of the uterine corpus","volume":"138","author":"Bonneterre","year":"2015","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2024.06.026_bb0110","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41392-020-0199-6","article-title":"Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence","volume":"5","author":"Wang","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"issue":"7","key":"10.1016\/j.ygyno.2024.06.026_bb0115","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.7150\/jca.41943","article-title":"Estrogen receptor, progesterone receptor, and HER2 receptor markers in endometrial Cancer","volume":"11","author":"Wang","year":"2020","journal-title":"J. Cancer"},{"issue":"18","key":"10.1016\/j.ygyno.2024.06.026_bb0120","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1021\/jm9801915","article-title":"Discovery and preliminary SAR studies of a novel, nonsteroidal progesterone receptor antagonist pharmacophore","volume":"41","author":"Pooley","year":"1998","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.ygyno.2024.06.026_bb0125","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1074\/jbc.271.2.1209","article-title":"Two types of anti-progestins have distinct effects on site-specific phosphorylation of human progesterone receptor","volume":"271","author":"Beck","year":"1996","journal-title":"J. Biol. Chem."},{"issue":"1\u20132","key":"10.1016\/j.ygyno.2024.06.026_bb0130","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jsbmb.2008.11.015","article-title":"Global gene expression profiling of progesterone receptor modulators in T47D cells provides a new classification system","volume":"113","author":"Afhuppe","year":"2009","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"10","key":"10.1016\/j.ygyno.2024.06.026_bb0135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0204973","article-title":"Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers","volume":"13","author":"Cottu","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ygyno.2024.06.026_bb0140","series-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5","author":"Department of Health and Human Services, N.I.o.H., National Cancer Institute","year":"2017"},{"key":"10.1016\/j.ygyno.2024.06.026_bb0145","series-title":"Progesterone","author":"Biosystems","year":"2024"},{"issue":"1","key":"10.1016\/j.ygyno.2024.06.026_bb0150","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ygyno.2003.11.008","article-title":"Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a gynecologic oncology group study","volume":"92","author":"Fiorica","year":"2004","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2024.06.026_bb0155","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2024.06.026_bb0160","doi-asserted-by":"crossref","first-page":"5601","DOI":"10.1200\/JCO.2023.41.16_suppl.5601","article-title":"OATH trial: a phase II clinical trial evaluating the combination of onapristone with anastrazole for women with hormone receptor positive endometrial cancer-Preliminary results","volume":"41","author":"Schilder","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2024.06.026_bb0165","doi-asserted-by":"crossref","first-page":"R15","DOI":"10.1530\/REP-14-0416","article-title":"Antiprogestins in gynecological diseases","volume":"149","author":"Goyeneche","year":"2015","journal-title":"Reproduction"},{"issue":"2","key":"10.1016\/j.ygyno.2024.06.026_bb0170","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1158\/1535-7163.MCT-17-0006","article-title":"Inhibiting nuclear phospho-progesterone receptor enhances antitumor activity of onapristone in uterine cancer","volume":"17","author":"Huang","year":"2018","journal-title":"Mol. Cancer Ther."},{"issue":"30","key":"10.1016\/j.ygyno.2024.06.026_bb0175","doi-asserted-by":"crossref","first-page":"4779","DOI":"10.1200\/JCO.22.02624","article-title":"Relacorilant + nab-paclitaxel in patients with recurrent, platinum-resistant ovarian cancer: a three-arm, randomized, controlled, open-label phase II study","volume":"41","author":"Colombo","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.ygyno.2024.06.026_bb0180","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.18632\/oncotarget.27989","article-title":"Glucocorticoid receptor antagonism promotes apoptosis in solid tumor cells","volume":"12","author":"Greenstein","year":"2021","journal-title":"Oncotarget"},{"issue":"15","key":"10.1016\/j.ygyno.2024.06.026_bb0185","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1158\/1078-0432.CCR-21-4363","article-title":"Overcoming taxane resistance: preclinical and phase 1 studies of relacorilant, a selective glucocorticoid receptor modulator, with nab-paclitaxel in solid tumors","volume":"28","author":"Munster","year":"2022","journal-title":"Clin. Cancer Res."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825824003512?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825824003512?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T01:31:06Z","timestamp":1728351066000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825824003512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":37,"alternative-id":["S0090825824003512"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.06.026","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Basket study of oral progesterone antagonist onapristone extended release in progesterone receptor-positive recurrent granulosa cell, low-grade serous ovarian cancer, or endometrioid endometrial cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.06.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}